MNPR
Monopar Therapeutics Inc. Common StockRecent alerts on MNPR
All signals →
SEC filing
MNPR Reports Positive Phase 2 ALXN1840 Data, Shows -0.37mg Daily Copper Balance Change, 50% Increase in Fecal Copper Output-to-Intake Ratio
13d ago
SEC filing
MNPR Presents Phase 3 Neurologic Wilson Disease Data, ALXN1840 Shows 45% Improvement vs 32% SoC, Durable Benefit, Favorable Safety
43d ago
News
Reynolds Consumer Products outlines flat 2026 adjusted EBITDA outlook as competitive pressures intensify
118d ago
News
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
153d ago
Scanner
Unusual volume (z=3.5)
160d ago
Scanner
Unusual volume (z=3.5)
162d ago
Scanner
Unusual volume (z=3.5)
163d ago
Scanner
Unusual volume (z=3.5)
164d ago
Get push alerts for MNPR
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS